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Phorbol 12-myristate 13-acetate (100 nM). a potent protein kinase Cand maerophagc activator, haz a bipha$ic affect on 2$(OH)D~-l~t-hydroxyla~ 
activity in syaovial fluid macrophages from arthritis patients. After 5 h, Ig,2S(OH)D~ synthesis fell from 5.2 _+ 0.1 to 1.6 :t: 0.2 pmol/h per 10~ cells. 
however, after 24 h and 48 h, synthesis increased to 17.4 _ 0.3 and 22.3 _+ 1.4 pmol/h per 10 ~ mils, resp~tivcly. Although an independent short-term 
mechanism i~ sug~ted0 protein kina~ C may promote macrophaBe activation, thus increasing long.term 25(OH)Dclc,-hydroxyla.s¢ cxpre~ion. 
lntracellular calcium and cAMP are unlikely to activate he enzyme, since 0.1 .aM of the calcium ionophore, A23187, and 1 mM dibutyryl-cAMP 
inhibited syntlte~is by87% and 79%, respectively, after 24 h. 
Macrophage; I~,25-(OH):D~; Inflammatory arthritis; Phorbol ester; Cyclic AMP; Calcium ioaophore A23187 
1. INTRODUCTION 
The active metabolite of vitamin D3, l~,25(OH).~D~ 
(l~,25-dihydroxyvitamin D~), is synthesized from 
25(OH)D~(25-hydroxyvitamin D~) by activated macro. 
phages (Me), as well as by kidney and placental cells. 
l~,25(OH)2D~ synthesized by all these cells not only 
fulfils different functions, but is regulated by different 
mechanisms [1,2]. For example, hypoealcaemia pro- 
motes parathyroid hormone-mediated l~,25(OH)2D3 
synthesis by a cAMP-dependent mechanism in kidney. 
Renal l~,25(OH).~D~ increases intestinal calcium ab- 
sorption, stimulates osteoblast function, inhibits its own 
synthesis and increases formation of 24,25(OH)~D3, 
which is normally the predominant renal metabolit¢ [3]. 
In contrast, lct,25(OH)~D~ is the primary non-placental 
extra-renal metabolite formed by Me activated by pul- 
monary sarcoidosis [4--6], tuberculosis [7], lymphoma 
[8], peritonitis [9] and arthritis [10-13]. 24,25(OH)2Ds i
not normally formed by activated Me but can be 
formed by monocytes and immature Me [14,15]. In pa- 
tients, excess l~,25(OH)2D~ synthesis may cause hyper. 
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l~,25-dihydrox~itamin D~; 24,25(OH)~D~, 24 25-dihydroxyvitamin 
D3; cAMP, cyclic adenosine monophosphate; M~,maerophage; IP'~- 
7, interferon-gamma; TNF-~, tumour necro~i,~ factor-alpha; Lr"S, 
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calcaemia which can be controlled by glucoeorticoids; 
this phenomenon is typical of extra-renal formation 
[16]. Synthesis of l~,25(OH)2D~ is induced by Me-acti- 
vating factors including, interferon-gamma (IFN-7) 
[6,17], turnout necrosis factor-alpha (TNF-a) [ 18] and 
bacterial ipopolysaeeharides (LPS) [19]. In addition, 
leukotriene C~, a distal metabolite in the arachidonic 
acid 5-1ipoxygenase pathway may also stimulate [20], 
whilst, prostaglandins El and E2 formed by the cyclo- 
oxygenase pathway, inhibit synthesis [12]. Further stud- 
ies have suggested that the calcium ionophore, A23187, 
can increase la~,25(OH)2D~, whilst phorbol 12-myristate 
13-acetate (PMA)0 a protein kinase C (PKC) activator 
and cyclic adenosine monophosphate (cAMP) do not 
affect synthesis [6,20,21], however, PMA will promote 
synthesis in the monoblastic U937 cell line [22]. Since 
the intracellular egulation of 25-(OH)D3-1¢x-hydrox- 
ylase activity in Me is still poorly understood, particu- 
larly with respect o arthritis, we have inv~tigated the 
effects of PMA, dibutyryl cAMP and the calcium iono- 
phore, A23187, on hx,25(OH)2D3 synthesis by synovial 
fluid Me cultured fi'om arthritic joints. 
2. MATERIALS AND METHODS 
2.1. Culture of synovial fluid Me 
• Synovial fluid Was obtained from the knees of 3 patients with active 
rheumatiod arthritis and 2 with inflammatory p~udosout. Each pa- 
tient was diagnosed on the bash of clinical criteria nd synovial fluid 
total and differential white all counts upplemented by appropriate 
immunological, r diologie.al and crystallographic inv~fiBationn. Sam- 
ples were diluted (4-16% v/v) in RPMI-1640 m~liam containing 2% 
heat-inactivated foetal calf .~rum, 2 mmol/! glutatnine, 100/~g/ml 
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Fig. 1. HPLC analyses of [3H]25(OH)D~ metabolism by untreated 
synovial fluid Mo (G--9)compared to cells treated with 100 nM PMA 
for 24 h (O---O). 0.31× 106 cells were inc abated with ['~H]25(OH)D.~ for
5 h after a total of 13 days in culture followlngisolation from a patient 
with pseudogout. Each point represents he radioactivity in eluent 
fractionz collected following chromatography on a normal phase 
HPLC system developed with n-hexane/i~opropanol/methanol 
(110:3.3:4 by vol.) at a flow rate of 2 ml/min. The standards trace 
(-*-) shows the retention times of authentic [~H]25(OH)D~, 
[~HJ24,25-(OH)_~D.~ and ['~H]Ia,25(OH),D.1. 
streptomycin and 100 IU/ml penicillin (Imperial Laboratories); for 
each sample the dilution depended on the volume and the cell density. 
Aliquots (2 or 4 ml) were plated directly into one or more 24- or 
12-well culture dishes (Imperial Laboratories). Following 48-72 h 
culture in an atmosphere 0f95% air/5% CO: at 37"C the non-adherent 
cells, predominantly l mphoc)'tes and apoptopic polymorphs, were 
dt.~:anted leaving adherent Me; the 2% serum.RPMl.1640 medium 
was then changed every 3-4 days. The Me were used alter 6-24 days 
in primary culture during which time they had developed from imma- 
ture monoeytes into adherent Me. Experiments examined the time- 
coates add dose-response to 1-100 nM PMA (Sigma) on the synthesis 
of lg,25(OHhD3 by cultured Me, Further experiments examined the 
affects or dibutyryl.eAMP (0.01-1 mM; Sigma) and the calcium iono- 
phore, A23187 (0.01-1 /.tM; Sigma) on 25-(OH)D.a.l~-hydroxylase 
activity. 
2.2. Assay of 2#-( OH) D~-Ig-hydro.v),ta~'e ctctiviO, 
The assays of 25(OH)D.~ metabolism were carried out in situ in 2 
ml of serum-free RPMI-1640 incubation medium containing 1.5 rag/ 
ml of bovine serum albumin (Immuno Diagnostika), 50,000 dpm 
[~H]25(OH)D~ (6.5 TBq/mmol, Amersham International), 0.125 nmol 
25(OH)D~ (25 ng/ml, Roussel UCLAF) for 5 h in an atmosphere of
95% air/5% C02 at 37"C. Incubations were carried out in triplicate for 
each concentration f test substance and were terminated by mixing 
the incubation medium with 3 ml ofchlorofonn and 2 ml of methanol. 
The extracts were centrifuged at500g for 15 rain at 4°C and the lower 
chloroform layer containing vitamin D 3 metabolites removed, dried 
under a stream of nitrogen gas, resuspended in I ml of ethanol and 
stor.~d at -20*C. Each chloroform extract was analyzed by normal 
phase high perlbrmance liquid chromatograph)' (HPLC) using a mo- 
bile phase of n.hexane/propan.2.ol/methanol, 110:3.3:4 by vol. at 2 
ml/min, a model 6000A HPLC solvent delivery pump (Waters Associ- 
ates) and a Zorbax-Sil column (6.2 mmx 4.6 era, Du Pont). Fractions 
were collected using a model 202 Fraction collector (Oilson) and radi- 
oactivity estimated on a liquid scintillation counter (1217 Rackbeta 
I.KB Wallac). Authentic tritium-rabelled 25(O1-1)D~, 24,25(OH),D~ 
and I~t,25(OH):D 3 (Amersham International) were also ehromato~ra- 
phed to determine the HPLC retention time for each metabolite. For 
each experiment cells were eounled in duplicate and the values used 
to normalis¢ 25(OH)D3-1a.hydroxylase activity for cell number. Syn- 
thesi~ o1" la,25(OH),D,~was expressed as pmol/h per 106 cells (means 
__. S.E.M.) of triplicate determinations. Statistical nalysis was carried 
out using Student's t-test and significance expressed as *(P.~0.05) or 
**(P<0.01) compared to controh. 
3. RESULTS AND DISCUSSION 
After 6-24 days in primary culture and a 5 h incuba- 
tion with [~H]25(OH)~D3 the conversion of substrate to 
[3H]hx~25(OH)D~by untreated synovial fluid Me 
ranged from 1.7 to 39.4%, representing 1.8-72.4 pmol 
10h25(OH),D#h per 10 ~ cells. Fig. 1 shows typical 
HPLC analyses of [3H]25(OH)D3metabolism by Me 
from a patient with pseudogout. Cells exposed to the 
PKC activator, PMA, (100 nM) for 24 h synthesized 
significantly more [3HI 10:,25(OH)_~D3 (17.7%) from the 
substrate conapared to untreated cells (5.3%); Fig. 1 also 
shows th'~t the Me did not synthesize 
[3H]24,25(OI-I)zD3, unlike kidney cells [3]. Fig. 2a illus- 
trates that stimulation of l~,25(OH).~D~ synthesis by 
PMA in twe. samples dose-dependently increased from 
1.8 + 0.2 to 14.1 + 0.8 and 5.7 + 0.9 to 20.9 + 1.8 pmol/h 
per 106 cells (P<0.01), respectively, after 24 h. However, 
after 5 h exposure PMA inhibixed 1,25(OH)2D3 synthe- 
sis compared to 24 h and 48 h treatments (Fig. 2b). 
These results uggest that independent long- and short- 
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Fig. 2. Effects of PMA on Icz,25(OH):D.~ synthesis by synovial fluid 
Mo (a), PMA dose-response (24 h) using ceils from two patients with 
rheumatoid arthritis after I0 Co---o) and 13 days (o--o) in culture, and 
(b) PMA time-course (100 nM) using cells from patients with pseu- 
dogout (o--o) and rheumatoid arthritis (o---o) after 6 and 24 days 
culture, respectively. Assays of 25(OH)D~.lrt.hydroxylase ctivity 
were carried out over 5 h using 0.28-0.35×10 f' Mo. Values are the mean 
_+ S.E.M. of 3 determinations (*P<0.05, **P<0.01). 
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Fig. 3. Effects of (a) dibutyrl-cAMP and (b) calcium ionophore 
(A23187) after 24 h on I",,25(OH),D.~ synthesis by synovial fluid Mt~ 
from patients with rheumatoid arthritis and pseudo/gout alter 13 and 
11 days culture, respectively. Assays of 25(OH)D~-I0t-hydroxylase 
activity were carried out over 5 h using O.08-0.1xlO ~'Me. Values are 
the mean ___ S.E.M. of 3 detemainations (*P<0.05, **P<0.01). 
term mechanisms may be involved. The long-term stim- 
ulation of 25-(OH)D;l~-hydroxylase by PMA may be 
mediated by PKC-mediated Mo maturation and activa- 
tion [21,22]. These results also suggest that induction of 
lcz,25(OH)D3synthesis by other Mo activators, includ- 
ing IFN-y [6,17], TNF-cz [18] and LPS [19], may in part 
be mediated by PKC. 
Normally PKC activation results from ligand-recep- 
tor-mediated synthesis of diacylglycerol and inositol- 
1,4~5-triphoshate (IP3) from phosphoinositol-4,5-bis- 
phosphonate (P1P,). Diacylglycerol stimulates PKC, 
which in turn phosphorylates proteins that mediate spe- 
cific biological actions, including cell differentiation 
[21-23]. In contrast, IP.~ mediates calcium release from 
the endoplasmie r ticulum which promotes various cel- 
lular events [23]. The calcium ionophore, A23187, may 
mimic the effects of IP3 by allowing extracellular cal- 
cium to enter cells; in our experiments, A23187 inhib- 
ited 25-(OH)D3-1g-hydroxylase activity in synovial 
fluid Me in a dose-dependent manner; likewise, dibu- 
tyryl cAMP inhibited l~x,25(OH)D3synthesis (Fig. 3). 
These results suggest hat IFN-y, TNF-cz or LPS-in- 
duced l~z,25(OH)D3synthesis i  unlikely to be mediated 
by raised intracellular Ca (Ca~) or by cAMP. However, 
our results differ from those reported for sarcoid Me 
where 10 -c' M A23187 stimulated synthesis [20]. Our 
results uggest that the short-term response to PMA or 
perhaps prostaglandin E~- and E.~-mediated inhibition 
of 25-(OH)D3-l=-hydroxylase [13]may be mediated by 
raised Ca~ or cAMP. 
Severe bone, cartilage and synovial tissue dt:struction 
occurs in arthritis as a result of complex immune inter- 
actions [24-26]~ some of which may be modulated by 
lg,25(OH)Da following binding to specific intraccllular 
receptors that are expressed by lymphocytes [2,27-29], 
monooytes [2,281, synoviocytes (ftbroblasts) [30] and 
bone ce!!s [1]. Locally synthesized Icz,25(OH):D~ 
formed by Mo in the arthritic joint may inhibit inter- 
leukin-2 production by T-lymphocytes reducing prolif- 
eration of T- and B-lymphoeytes [2,31], promote the 
differentiation fmonocytes into Mo [22,28,32] and the 
fusion of Me to multinucleated M,~ with bone resorbing 
activity [33]. It is therefore necessary todetermine which 
factors regulate Ig,25(OH).~D~ synthesis in M¢~ at an 
e~ttracellular nd intracellular level in order to evaluate 
the role of this metabolite in inflammatory disease. In 
this study the data presented suggests that PKC may 
increase l=,25(OH)_~D3, whereas Ca~ and cAMP may 
inhibit synthesis. 
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